Other income decreased approximately $278,000 for the year ended April 30, 2012 compared to the prior year. The decrease in other income was primarily due to the non-recurring $244,000 award received in the prior year under the Patient Protection and Affordable Care Act of 2010 and a reduction in sublease revenue received in the current year.Other expense increased approximately $88,000 for the year ended April 30, 2012 compared to the prior year. The increase in other expense was primarily due to our write-off of an uncollectible receivable for reimbursable patent costs related to our terminated license agreement with Glucometrics, Inc., partially offset by a reduction in foreign currency translation losses.
Oxygen Biotherapeutics Reports Financial Results For Fiscal Year 2012
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.